Recombinant polynucleotides encoding CYP7 promoter-binding factors
AssigneesTularik Inc., Sumitomo Pharmaceuticals Company, Limited
InventorsBei Shan, Masahiro Nitta
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions relating to CPF proteins which regulate transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed CPF encoding nucleic acids or purified from human cells. The invention provides isolated CPF hybridization probes and primers capable of specifically hybridizing with the disclosed CPF genes, CPF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
Claims20
A recombinant polynucleotide comprising a cDNA which comprises a coding region encoding a polypeptide comprising:
- (a) SEQ ID NO:2, 4, or 6, or (b) at least ten contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15 and 16-21 of SEQ ID NO:2, or (c) at least ten contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome.
A recombinant polynucleotide comprising a coding region encoding a polypeptide comprising at least ten contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residues 150-159 of SEQ ID NO:4.
A recombinant polynucleotide comprising a cDNA which comprises a coding region encoding a polynucleotide comprising at least 32 contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residue 154 of SEQ ID NO:4, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome.
A recombinant polynucleotide comprising a cDNA which comprises a sequence selected from, (a) the group consisting of SEQ ID NO:1, 3 and 5 or (b) the group consisting of nucleotides 1-26, 52-62, 1630-1650, 1790-1810, 1855-1875, 1910-1925, 2566-2586, and 2666-2686 of SEQ ID NO:1, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome.
Dependencies are inferred from the claim text.